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High dose B-vitamin treatment of hyperhomocysteinemia in dialysis
patients. Hyperhomocysteinemia, an arteriosclerotic risk factor, persists in
75% of dialysis patients despite routine low dose supplementation with the
B-vitamin co-factors/substrates for homocysteine (Hey) metabolism, and
normal or supernormal plasma status of these vitamins (Atherosclerosis
114:93, 1995). We conducted a placebo-controlled eight-week trial of the
effect on plasma homocystcine of adding supraphysiologic dose folic acid
(15 mg/day), B-6 (100 mg/day), and B-12 (1 mg/day) to the usual daily
dosing of 1 mg folic acid, 10 mg B-6, and 12 jig B-12, in 27 hyperhomo-
cysteinemic dialysis patients. Total plasma homocystcine was measured at
baseline, and after four and eight weeks. Blinded analyses revealed no
evidence of toxicity in the group randomized to supraphysiologic dose
B-vitamin supplementation. Plasma homocysteine was significantly re-
duced after both four weeks (—29.8% vs. —2.0%; P = 0.0024) and eight
weeks (—25.8% vs. +0.6%; P = 0.0009) of active versus placebo treat-
ment. Also, S of 15 treated versus 0 of 12 placebo group patients had their
plasma Hey reduced to within the normative range (< 15 j.tmol/liter).
Supraphysiologic doses of B-vitamins may be required to correct hyper-
homocysteinemia in dialysis patients.
Atherothrombotic sequelac such as myocardial infarction (MI)
and stroke remain the leading cause of mortality in end-stage
renal disease (ESRD) patients on maintenance dialysis [1]. De-
spite their reportedly high prevalence [2], the predictive value of
traditional cardiovascular disease (CVD) risk factors in determin-
ing CVD outcomes in ESRD remains limited [3].
Homocysteine (Hey) is a sulfur-containing amino acid product
of methionine metabolism. A review [I of 20 retrospective case
control studies involving —4800 patients and an equal number of
controls indicated that moderate hyperhomocysteinemia, either
fasting or after oral methionine loading, was an independent risk
factor for premature coronary heart, cerebrovascular, or periph-
eral vascular disease. Two large prospective studies subsequently
confirmed that moderate hyperhomocysteinemia was an indepen-
dent predictor of incident MI, after controlling for a wide range of
known CVD risk factors [5, 6]. Most recently, population-based
data from the original Framingham Study cohort revealed that
plasma Hey levels in the upper quartile were associated with a
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two-fold increased risk for extensive extracranial carotid arterio-
sclerosis, which persisted after adjustment for age, smoking,
hypertension, and dyslipidemia [7].
Plasma Hey levels determined as the acid-soluble mixed disul-
fide homocysteine-cysteine were first shown to be increased in
chronic renal failure by Wilcken and Gupta [81. Subsequent case
control studies have revealed markedly elevated plasma levels of
acid-soluble [9], protein-bound [10], or total Hey [11, 12] in ESRD
patients on peritoneal or hemodialysis, and non-dialyzed uremie
patients with varying degrees of renal impairment. We recently
confirmed these case control findings, and also demonstrated that
hyperhomocysteinemia was more prevalent, with a dramatically
greater prevalence odds than any of the traditional CVD risk
factors, in maintenance dialysis patients [13, 14]. Furthermore,
hyperhomocysteinemia persisted in the dialysis patients despite
daily, near physiologic dose supplementation (that is, 2 to 5 X the
US RDA) with the B-vitamin co-factors/substrates for Hey me-
tabolism (folate, B-6, B-12), and normal or supernormal plasma
status of these vitamins [13, 14].
Folic acid supplementation at doses of between 0.65 and 5.0 mg
per day routinely normalizes fasting total plasma Hey in persons
who have intact renal function, and are not B-12 deficient [15—17].
B-6 supplementation is required to reduce or normalize the
post-methionine loading increase in Hey levels above fasting
levels [18]. These findings are consistent with what is understood
about the metabolism of Hey via the remethylation and transsul-
furation pathways [19]. In remethylation, the primary methyl
donor for the conversion of Hey to methionine is provided by the
reduction of methylenetefrahydrofolate to 5-methyltetrahydrofo-
late, the major circulating form of folate, by the enzyme methyl-
enetetrahydrofolate reductase (MTHFR). 5-Methyltetrahydrofo-
late serves as a one-carbon donor for the vitamin B-12-dependent
remethylation of Hey to methionine catalyzed by methionine
synthase. The remethylation enzymes have a low K for Hey, and
function to maintain normal fasting homocysteinemia. In the
transsulfuration pathway, Hey condenses with serine to form
cystathionine in an irreversible reaction catalyzed by the pyridox-
al-S '-phosphate (PLP)-containing enzyme, cystathionine beta syn-
thase (CBS). CBS has a high Km for Hey, and functions to
maintain normal postprandial or post-methionine loading homo-
cysteinemia [19]. These pathways appear to be disrupted most
commonly by deficiencies of three micronutrients [4, 5, 7; 15—18,
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20], two of which are cofactors (vitamins B-6 and B-12), and one
which is a substrate (folate).
A comprehensive review of the published clinical trial literature
failed to uncover a single report in which mean fasting total Hcy
levels were reduced to within the normal range (that is, < 15
jmol/liter; [20]) by any combination of B-vitamins in hyperhomo-
cysteinemic maintenance dialysis patients [21—23]. In addition,
none of these studies [21—23] were placebo-controlled so their
internal validity may have been compromised by regression to the
mean. Accordingly, we conducted a randomized eight-week trial
of the effect on plasma Hcy of adding supraphysiologic dose folic
acid, along with B-6, and B-12, versus placebo, to the usual dialysis
dosing of these vitamins in hyperhomocysteinemic maintenance
dialysis patients.
Methods
Study population
Thirty-two maintenance dialysis patients involved in an ongoing
case-control studies of hyperhomocysteinemia and traditional
cardiovascular disease risk factors [13, 141 were recruited from
four Brown University-affiliated outpatient dialysis centers for the
present study. Exclusion criteria included age > 75 or < 30 years
old, malnutrition (that is, albumin < 2.0 mgldl or protein catabolic
rate <0.8), rejection of a cadaveric or living-related donor kidney
transplant within six months of the current study, and current use
of antifolate or anticonvulsant medications. All participants had
fasting total plasma Hey levels  16 jtmol/liter when determined
as part of the initial case-control studies. Nearly 50% of those
patients with screening Hey levels  16 tmol/liter (32 of 63)
agreed to participate. The study protocol was approved by the
Rhode Island Hospital Institutional Review Board, and all par-
ticipants gave their written informed consent prior to participa-
tion. Individuals were block randomized into two groups of 16 on
the basis of fasting Hey > 30 jimol/liter, fasting folate < 6 ng/ml,
sex, mode of dialysis (peritoneal vs. hemodialysis), and race.
Subsequent to randomization, but prior to actual initiation of the
intervention study, four subjects in the placebo group dropped out
due to lack of continued interest, while one subject in the active
treatment group could not participate due to intercurrrent coro-
nary artery bypass graft surgery. Twenty-seven subjects completed
four or eight weeks of the study, 12 randomized to the placebo
group, and 15 randomized to the active treatment group. One
subject in the placebo group missed the blood draws after four
weeks of treatment due to hospitalization for a below knee
amputation, but remained in the study, and underwent the
post-eight week blood draws. An additional subject in the active
treatment group hospitalized for an exacerbation of chronic
peptic ulcer disease was unavailable for the post-eight week blood
draws, but underwent the blood draws after four weeks of
treatment. Characteristics of the (N = 27) participants who
completed all or part of the intervention study were: (a) mean age
(± SD) 56 (± 13) years, range 35 to 73 years; (b) etiology of
ESRD: diabetic nephropathy (N = 5), hypertensive nephroscle-
rosis (N = 6), glomerulonephritis (N = 7), polycystic kidney
disease (N = 2), and unknown/other (N = 7); (c) sex: 14 men, 13
women; (d) mode of dialysis: 20 hemodialysis, 7 peritoneal
dialysis; and (e) race: 22 white, 5 black. Baseline Hey data (visits
1 and 2 averaged) were available from 31 of the original 32
patients who initially agreed to participate. There was no differ-
ence in baseline Hey levels between the 4 dropouts and the 27
patients who completed all or part of the study (30.6 btmol/liter vs.
29.5 jtmol/liter, respectively, P = 0.638 by Mann-Whitney U-test).
Laboratory and clinical data acquisition
Phlebotomy was performed non-fasting, pre-dialysis (hemodi-
alysis) or random dwell (peritoneal dialysis), twice 48 to 72 hours
apart at baseline, and after four weeks and eight weeks of active
or placebo treatment. Three of these six blood draws were
synchronized with the patients' routine monthly phlebotomy to
decrease participant burden. All whole bloods were immediately
cooled at 4°C, and the plasma or serum separated within four
hours in a refrigerated centrifuge. Total homocysteine (Hey), the
sum of the acid-soluble (that is, reduced Hey, homocystine
disulfide, and homocysteine-cysteine mixed disulfide) and protein-
bound moieties, was determined in EDTA plasma by a modifica-
tion of the fluorimetric high performance liquid chromatography
(HPLC) method originally described by Araki and Sako [24]. In
brief, this assay involves the following steps: reduction of the
sample with tri-n-butylphosphine, precipitation of proteins, alka-
linization of the supernatant with sodium borate, derivitization
with SBDF (7-fluoro-2-oxa-1,3 diazole-4-sulphonate), followed by
ANTS (8-aminonapthalene-1 ,3,6-trisulfonic acid, sodium salt),
and HPLC Separation with fluorescence detection. SBDF is a
fluorescence probe for compounds containing SH groups, and
ANTS is used as an internal standard because of its natural
fluorescence at 515 nanometers when excited at 385 nanometers,
the same wavelengths used for the detection of the SH/SBDF
adducts. The inter- and intra-assay coefficients of variation for this
assay are routinely < 5%. Plasma pyridoxal 5'-phosphate (the
active metabolic form of B-6) was assessed enzymatically using
tyrosine decarboxylase [25]. Plasma folate was measured by a
96-well plate microbial (Lactobacillus casei) assay [26], and
plasma B-12 with a (Magic) radioassay from CIBA-Corning. To
minimize interassay variability, the Hey and vitamin assays were
performed "batched" for each patient from all six study visits in
thawed plasma aliquots that had been cryopreserved at —70°C for
 14 weeks. Routine monthly serum clinical chemistry profiles
and hematocrit determinations were performed using standard
methods. A symptoms questionnaire was administered to each
participant at the end of the study. Eight week compliance with
the treatment and placebo regimens was assessed by pill count. All
data collection was performed blinded to treatment group assign-
ment.
Treatment regimens
The treatment design was randomized and placebo-controlled,
and the treatment group assignment code was not broken until
data entry and analysis were completed. Treatment consisted of
15 mg folic acid, 100 mg B-6, 1 mg B-12, and cellulose fiber, or
matched placebos containing only cellulose fiber, orally adminis-
tered in single tablets taken once daily in the evening. All
participants continued their prescribed daily oral supplementation
with 1 mg folic acid, 10 mg B-6, and 12 .tg B-12, throughout the
study.
Statistical analyses
A priori, we estimated that the study had > 90% power to detect
the expected effect size of 0.30 (that is, a 30% lowering of plasma
Hey with active treatment relative to 0% lowering with placebo
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Placebo
(N = 12)
Active
(N = 15) P valueb
Hcy (nnol/liter) 29.6 6.3a 29.5 10.0 0.733
Folate (ng/ml) 49.3 25.6 32.5 25.1 0.079
N (%) Hemodialysis 8 (66.7) 12 (80.0) 0.73 1
N (%) Men 7 (58.3) 7 (46.7) 0.830
N (%) White 10 (83.3) 12 (80.0) 0.782
treatment) given N = 12 subjects per group. Active versus placebo
group baseline differences were evaluated by Mann-Whitney
U-tests, and chi square tests. Means of the two baseline minus two
four-week or two eight-week ("delta") Hey levels were compared
by unpaired t-tests and Mann-Whitney U-tests. In addition, linear
regression models were constructed with baseline minus four or
eight week Hey levels as the outcome variable, and treatment
group, baseline Hey, folate, and PLP as the independent variables.
Mean baseline minus eight-week ("delta") alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST), creatinine, and
hematocrit values in the active versus placebo groups were also
compared by unpaired t-tests. Differences in reported symptom
frequency in the active versus placebo treated groups were
assessed by chi square analyses. Reported P values are based on
two-tailed calculations. All statistical analyses, including the block
randomization procedure outlined earlier, were performed using
SAS [27].
Results
Key baseline characteristics in the two groups were comparable,
indicating that block randomization was successful (Table 1).
Eight week compliance by pill count was 75.1% in the active
treatment and 86.7% in the placebo groups, respectively. Signifi-
cant increases (Table 2) in mean plasma B-vitamin levels in the
active treatment group provided confirmation of the pill count
compliance data. Active versus placebo treatment also resulted in
a significant mean reduction in total plasma Hey of —29.8%
versus —2.0% (P = 0.0024) at four weeks, and —25.8% versus
+ 0.6% (P = 0.0009) at eight weeks, by unpaired t-tests (Table 2).
These findings were confirmed by Mann-Whitney U-tests (4
weeks, P = 0.0028; 8 weeks, P = 0.0012). Linear regression
analyses further demonstrated that active treatment was the
strongest independent predictor of both baseline minus four
weeks (beta =
—7.21, t = 3.358; P = 0.003) or eight weeks (beta
—6.32, t = 3.833; P = 0.001) Hey levels in models that included
treatment group assignment, and mean baseline folate, PLP, and
Hey. This indicates that after adjustment for treatment group
assignment and mean baseline vitamin status and Hey levels, Hey
levels were 7.21 imol/1iter lower at four weeks and 6.32 .tmo1/1iter
lower at eight weeks in the active treatment group compared with
the control group, and this effect was highly significant. A trend
(P = 0.086; ehi square with continuity correction) for "normal-
ization" (that is, reduction to < 15 .tmol/liter) of plasma Hey was
observed in the active treatment (5 of 15) versus placebo group (0
of 12). Active treatment was not associated with an increased
frequency of any specific symptoms (Table 3), or adverse changes
in hematocrit, AST, ALT, or creatinine (Table 4).
Discussion
Our study design mimicked the routine clinical setting, that is,
monthly determination of non-fasting plasma/serum chemistries,
and the placebo group provided confirmation [12] that non-fasting
pre-hemodialysis or random dwell (peritoneal dialysis) plasma
Hey is a stable outcome measure. The data reported here provide
the first placebo-controlled demonstration that much larger daily
doses of B-vitamins (that is, folic acid, B-6, and B-12) can
significantly augment the Hey-lowering effect of the near physio-
logic dose B-vitamin supplements usually given to maintenance
dialysis patients. Furthermore, we found no evidence of toxicity
associated with this supraphysiologie dose B-vitamin treatment
regimen, based upon blinded analyses of routine monthly clinical
chemistry profiles and responses to a comprehensive symptoms
questionnaire. More prolonged studies of comparable or higher
dose folie acid-based Hey-lowering regimens need to be per-
formed in larger groups of maintenance dialysis patients to
confirm and extend the current findings.
As anticipated due to their routinely prescribed near physio-
logic dose supplementation, mean baseline folate levels in both
groups of patients (treated 32.5 ng/ml; placebo 49.3 ng/ml) far
exceeded the 90th percentile folate levels in age, sex, and race
matched Framingham Study controls with normal renal function
[13, 14]. It remains unclear why hyperhomoeysteinemic mainte-
nance dialysis patients often respond inadequately [10—14; 21—23]
to doses of folic acid alone, or in combination with B-6 and B-12,
that consistently normalize plasma Hey in hyperhomocysteinemic
persons with intact renal function who are not homozygous for
severe Hey-metabolizing enzyme deficiencies [15—18]. Given the
extensive plasma protein-binding (—70 to 80% of total [28]) and
resultant limited renal filtration of unbound Hey, loss of urinary
Hey excretion is probably not responsible for this refractory
hyperhomocysteinemia. Indeed, there is evidence that loss of the
normally avid tubular reabsorption of the freely filterable un-
bound fraction of Hey offsets the decline in its glomerular
filtration in ESRD [12]. Substantiation of the hypothesis that
there may be considerable metabolism of Hey by normal renal
parenehyma [28] has recently been provided by in vivo data from
an established rat model [29]. Determination of arteriovenous
Hey differences across the rat kidney, along with simultaneous
assessment of renal plasma flow, urine flow, and urinary Hey
concentration, revealed substantial Hey uptake by normal rat
kidneys, and confirmed that urinary Hey excretion is minimal [29].
These data suggest that loss of the large Hey-metabolizing capac-
ity of normal kidneys may be an important determinant of the
refractory hyperhomocysteinemia commonly observed in ESRD.
Livant et a! [30] recently reported sizable folate losses into the
dialysate, and the presence of an unidentified heat-stable inhibi-
tor(s) of folate conjugase in hemodialysis patients. Folate conju-
gase cleaves glutamyl residues of polyglutamyl folates and this
alteration of chain lengths is believed to be crucial to the function
of both folate requiring, and perhaps other co-factor dependent
co-enzymes [31]. Inhibition of folate eonjugase may result in the
accumulation of long chain length polyglutamated folates despite
folate supplementation in ESRD patients. Maintenance of a high
ratio of long versus short chain length folates could adversely
affect the activity of Hey-metabolizing enzymes (such as CBS,
Table 1. Key baseline patient characteristics
a Mean of two baseline values standard deviation
b Two-tailed value based on Mann-Whitney U-test or chi square test
with continuity correction
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Table 2. Effect of active vs. placebo treatment on plasma homocysteine and B-vitamin levels
Group 0 weeks 4 weeks
4-0 weeks
% change 8 weeks
8-0 weeks
% change
Treated (N = 15)
Hey jvnoilliter
Folate ng/ml
PLPpmol/mi
B-12 pg/mi
Placebo (N = 12)
Hey
Folate
29.5 10.0"
32.5 25.1
67.2 81.0
468.6 308.6
29.6 6.3
49.3 25.6
20.7 8.0
926.8 574.9
200.6 204.2
1271.7 466.7
29.2 6.2'
47.1 32.9
—29.8"
+2751.7"
1985g
+171.4
—2.0
—4.5
21.9 7.7
707.6 507.2
183.6 146.4
1348.4 563.9
29.8 6.3
53.8 67.2
—25.8""
+2O77.2
+173.2"
+187.8"'
+0.6
+9.1
PLP 112.6 88.8 133.3 91.4 + 18.4 134.9 100.4 +19.8
B-12 649.7 244.0 638.9 261.9 —1.7 527.3 159.0 —18.8
"Mean standard deviation for the average of two values at each time point
h Two-tailed P = 0.0024 vs. placebo change at 4 weeks based on unpaired t-test
'One subject in the treated group had blood drawn at 4 weeks but not 8 weeks, so (N = 14)
d Two-tailed P = 0.0009 vs. placebo change at 8 weeks based on unpaired t-test
Two-tailed P = 0.0001 vs. placebo change at 4 weeks based on unpaired t-test
Two-tailed P = 0.0002 vs. placebo change at 8 weeks based on unpaired t-test
g Two-tailed P = 0.070 vs. placebo change at 4 weeks based on unpaired t-test
h Two-tailed P = 0.045 vs. placebo change at 8 weeks based on unpaired t-test
Two-tailed P = 0.0001 vs. placebo change at 4 weeks based on unpaired t-test
k Two-tailed P = 0.0003 vs. placebo change at 8 weeks based on unpaired t-test
'One subject in the placebo group had blood drawn at 8 weeks but not 4 weeks, so (N = 11).
Table 3. Frequency of symptoms active vs. placebo treatment groups
Symptom
Acti
(N =
ye
14)
Place
(N =
bo
12) P valuea
Nausea 1 2 0.887
Heartburn 2 3 0.848
Diarrhea 5 2 0.5 17
Constipation 3 0 0.276
Rash 0 0 —
Itching 5 9 0.108
Muscle aches 4 3 0.811
Muscle spasms 2 3 0.848
Tiredness/weakness 3 3 0.802
Fainting 0 0 —
Nervousness 2 1 0.887
Headaches 4 3 0.811
Sleep problems 6 6 0.976
Tingling in digits 4 3 0.811
Chest pain 0 2 0.394
Rapid heart beat 2 0 0.532
Nightmares 0 0 —
"Two-tailed value based on chi square comparison of reported symp-
toms during the 8th week of active vs. placebo treatment
which is PLP-dependent; Dr. C. Krumdieck, unpublished obser-
vation). Accordingly, supraphysiologic dose folic acid supplemen-
tation might be required to replace dialysate losses of folate,
favorably alter the folate chain length ratio, and promote Hey
metabolism in ES RD. Finally, Hultberg et al [12] have shown that
post-methionine load Hey levels are increased in ESRD patients
versus controls, suggesting a possible defect in B-6 dependent
transsulfuration of Hey in ESRD. An increased B-6 requirement
in ESRD would be less discernible by evaluating fasting Hey levels
[19], as was done in previous case control [13, 14] and intervention
[21] studies.
A burgeoning amount of experimental data have linked hyper-
homocysteinemia to atherothrombosis [32—391. Putative patho-
mechanisms include endothelial cell injury [32, 33], enhanced low
density lipoprotein oxidation [34], increased thromboxane-medi-
Table 4. Changes in liver transaminases, creatinine, and hematocrit
over eight weeks in the active vs. placebo treatment groups
Active
(N = 14)
Placebo
(N = 12) P value"
z ASTb mg/dl —1.3 5.4 —2.3 7.2 0.700
z ALT mg/dl —1.9 10.2 —2.3 8.5 0.900
Hematocrit % —0.4 1.5 —0.04 1.6 0.614
i/ Creatinine mg/dl +1.7 2.4 +0.7 3.0 0.390
"Two-tailed value based on unpaired t-test.
= mean standard deviation of 8-week minus 0-week values
ated platelet aggregation [35], inhibition of cell surface thrombo-
modulin expression and protein C activation [36], enhancement of
lipoprotein (a)-fibrin binding [37], and promotion of smooth
muscle cell proliferation [38]. Rolland et al [39] recently described
an elegant model of dietary-induced hyperhomocysteinemia and
vascular damage in the mini-pig. Future studies using this model
may elucidate the in vivo relevance of the studies cited above
[32—38]. Regardless of the specific pathomechanism(s), prospec-
tive observational data [5, 6], and Hey-lowering dietary interven-
tion (that is, B-vitamin, and/or betaine supplementation, and
restriction of methionine intake) data [40] suggest that hyperho-
mocysteinemia is associated with an increased incidence of
atherothrombotic events in non-uremic populations. Preliminary
subgroup analyses further indicate that hyperhomocysteinemia
may also be linked to prevalent atherothrombosis in uremic
patients not yet dialysis-dependent [11], and incident athero-
thrombosis in renal transplant recipients [41].
Despite a group mean lowering of ---26 to 30% in plasma Hey,
only 5/15 of the total number of treated patients, and 3 of 12
whose baseline Hey was > 20 jmol/liter had their Hey levels
reduced to within the accepted "normative range" (that is, < 15
tmol/liter; [20]) in the present study. Prevalence data from the
Framingham Study have revealed that there is already an in-
creased risk for extracranial carotid arteriosclerosis  25% (a
marker for significant generalized arteriosclerosis [42]) at plasma
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Hcy levels  11.1 mol/liter [71. Clearly, more effective therapeu-
tic regimens (higher dose combinations of dietary supplements
and/or improved dialysis removal of Hcy) that truly normalize
total plasma Hcy in maintenance dialysis patients need to be
developed. As reviewed by Butterworth and Tamura [43], folic
acid has been safely administered orally at doses of up to 60
mg/day for two years, and 500 mg/day for two weeks. More recent
data indicated no apparent toxicity of folic acid at 400 mg/day
given for two months to a child with homocystinuria due to
homozygous methylenetetrahydrofolate reductase deficiency [44].
Controlled studies of the Hey-lowering efficacy of folic acid given
in excess of 15 mg/day may be warranted in hyperhomocysteine-
mic maintenance dialysis patients. Identification of a safe, effec-
tive chronic Hey-lowering regimen could lead to placebo-con-
trolled interventions for primary and/or secondary prevention of
cardiovascular disease in maintenance dialysis patients. Such
clinical trials would evaluate the hypothesis that hyperhomocys-
teinemia contributes to atherothrombosis, and the findings might
be relevant to other hyperhomocysteinemic patient populations.
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